Establishing demographic-based normative values for neurofilament light chain and glial fibrillary acidic protein in serum and plasma samples
Multiple Sclerosis Journal - Experimental, Translational and Clinical · Published 2026-07-01 · DOI 10.1177/20552173261466440
Free full text
Authors (18)
Tyler L Borko, Alanna Ritchie, Sean Selva, Stefan Sillau, Eric Engebretson, Andrew B Wolf, Enrique Alvarez, Robert Gross, Eric Gutierrez, John Corboy, Diego Silva, Ryan Kammeyer, Amanda L Piquet, Timothy L Vollmer, Salim Chahin, Gregory Owens, Jeffrey L Bennett, Kavita V Nair
Abstract
Background Interpretation of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) levels in blood requires reference ranges from healthy cohorts, accounting for demographic features. Objective To compare serum and plasma NfL and GFAP in healthy individuals, accounting for age, sex, and body mass index (BMI). Methods Adolescents through older adults were recruited at Colorado community events and a senior clinic. A neurologist reviewed self-reported medical histories. Paired serum and EDTA plasma samples were assayed using the Quanterix SR-X Simoa Neuro 4-Plex. Log-linear models estimated percent change per year of age, per BMI unit, and sex ratios. GFAP used a piecewise age model (knot at 30 years). Spearman correlation assessed serum–plasma concordance. Results We enrolled 143 participants (ages = 16.4–85.9; 63.6% female; mean BMI = 26.7). Serum–plasma correlations were strong (NfL ρ = .923; GFAP ρ = .833; both p < .001). In plasma, age was associated with a 2.96% increase in NfL and 2.34% in GFAP per year for ages ≥30. In serum, NfL rose 2.90% and GFAP 2.69% per year (both p < .0001). Conclusion NfL and GFAP are strongly age-dependent and concordant across serum and plasma in healthy individuals. An online calculator provides age-, sex-, and BMI-adjusted reference estimates and serum/plasma conversions.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2026
Citation
Borko, T., Ritchie, A., Selva, S., et al. (2026). Establishing demographic-based normative values for neurofilament light chain and glial fibrillary acidic protein in serum and plasma samples. Multiple Sclerosis Journal - Experimental, Translational and Clinical. https://doi.org/10.1177/20552173261466440
Related articles
- Comorbidities in newly diagnosed multiple sclerosis patients: A population-based register study in Finland · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Hypogammaglobulinemia and infection rates in patients with multiple sclerosis treated with ocrelizumab for up to six years: A real-world single-center study · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal
- Real-world safety and effectiveness of ofatumumab in multiple sclerosis: A clinic-based study in Australia · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Men's health research priorities in men with multiple sclerosis · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Music therapy with a monochord in multiple sclerosis (“MUTIMS”): A randomized, controlled, rater-blinded trial · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal
- Deep cervical lymph node volume decreases following B-cell depletion therapy · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal
- Feasibility and preliminary outcomes of a remotely-delivered exercise training intervention for English-speaking Hispanics/Latinos with multiple sclerosis: Results from the FERLA MS study · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Discrepancy between subjective and objective cognitive function in multiple sclerosis and association with mood, fatigue, and pain · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Baricitinib triggering a central nervous system inflammatory-demyelinating disease: A case report · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Analysis of an innovative fluid biomarker panel for early prediction of progression independent of relapse activity in multiple sclerosis · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal